Cubist Systematic Strategies’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $182K | Sell |
1,300
-54,619
| -98% | -$7.38M | ﹤0.01% | 2678 |
|
|
2025
Q2 | $7.02M | Sell |
55,919
-84,962
| -60% | -$10.6M | 0.03% | 808 |
|
|
2025
Q1 | $19.3M | Buy |
140,881
+25,938
| +23% | +$3.71M | 0.12% | 212 |
|
|
2024
Q4 | $17.6M | Buy |
+114,943
| New | +$19.4M | 0.11% | 249 |
|
|
2024
Q2 | – | Sell |
-19,793
| Closed | -$4.3M | – | 3010 |
|
|
2024
Q1 | $4.27M | Buy |
19,793
+9,502
| +92% | +$2.23M | 0.02% | 1061 |
|
|
2023
Q4 | $2.66M | Buy |
10,291
+7,947
| +339% | +$1.95M | 0.02% | 1299 |
|
|
2023
Q3 | $602K | Buy |
2,344
+1,638
| +232% | +$438K | ﹤0.01% | 2208 |
|
|
2023
Q2 | $201K | Sell |
706
-1,073
| -60% | -$319K | ﹤0.01% | 2818 |
|
|
2023
Q1 | $495K | Sell |
1,779
-60,495
| -97% | -$16.7M | ﹤0.01% | 2663 |
|
|
2022
Q4 | $17.2M | Sell |
62,274
-47,692
| -43% | -$13.5M | 0.1% | 211 |
|
|
2022
Q3 | $29.4M | Buy |
109,966
+80,194
| +269% | +$17M | 0.17% | 60 |
|
|
2022
Q2 | $6.07M | Sell |
29,772
-88,061
| -75% | -$18M | 0.04% | 815 |
|
|
2022
Q1 | $24.8M | Buy |
117,833
+87,165
| +284% | +$19M | 0.21% | 33 |
|
|
2021
Q4 | $7.36M | Buy |
30,668
+17,700
| +136% | +$4.55M | 0.07% | 408 |
|
|
2021
Q3 | $3.67M | Sell |
12,968
-23,740
| -65% | -$7.78M | 0.05% | 630 |
|
|
2021
Q2 | $12.7M | Buy |
36,708
+32,173
| +709% | +$9.75M | 0.14% | 135 |
|
|
2021
Q1 | $1.27M | Sell |
4,535
-4,640
| -51% | -$1.25M | 0.02% | 1375 |
|
|
2020
Q4 | $2.25M | Sell |
9,175
-874
| -9% | -$225K | 0.03% | 877 |
|
|
2020
Q3 | $2.85M | Sell |
10,049
-4,839
| -33% | -$1.35M | 0.04% | 691 |
|
|
2020
Q2 | $3.98M | Sell |
14,888
-8,998
| -38% | -$2.7M | 0.07% | 449 |
|
|
2020
Q1 | $7.56M | Buy |
23,886
+6,381
| +36% | +$1.94M | 0.2% | 104 |
|
|
2019
Q4 | $5.19M | Sell |
17,505
-54,151
| -76% | -$15M | 0.1% | 295 |
|
|
2019
Q3 | $16.7M | Buy |
71,656
+12,230
| +21% | +$2.85M | 0.33% | 37 |
|
|
2019
Q2 | $13.9M | Buy |
59,426
+54,549
| +1,118% | +$12.6M | 0.26% | 66 |
|
|
2019
Q1 | $1.15M | Sell |
4,877
-12,406
| -72% | -$3.91M | 0.04% | 688 |
|
|
2018
Q4 | $5.2M | Sell |
17,283
-23,301
| -57% | -$7.44M | 0.25% | 52 |
|
|
2018
Q3 | $14.3M | Buy |
40,584
+35,981
| +782% | +$12.4M | 0.78% | 6 |
|
|
2018
Q2 | $1.34M | Buy |
4,603
+805
| +21% | +$226K | 0.07% | 363 |
|
|
2018
Q1 | $1.04M | Sell |
3,798
-12,244
| -76% | -$3.8M | 0.06% | 415 |
|
|
2017
Q4 | $5.11M | Buy |
16,042
+5,396
| +51% | +$1.73M | 0.27% | 34 |
|
|
2017
Q3 | $3.33M | Buy |
10,646
+6,409
| +151% | +$1.9M | 0.19% | 77 |
|
|
2017
Q2 | $1.15M | Sell |
4,237
-669
| -14% | -$177K | 0.07% | 368 |
|
|
2017
Q1 | $1.34M | Sell |
4,906
-2,358
| -32% | -$667K | 0.1% | 239 |
|
|
2016
Q4 | $2.06M | Buy |
7,264
+5,341
| +278% | +$1.58M | 0.16% | 141 |
|
|
2016
Q3 | $602K | Sell |
1,923
-280
| -13% | -$82.9K | 0.04% | 637 |
|
|
2016
Q2 | $533K | Sell |
2,203
-5,102
| -70% | -$1.34M | 0.03% | 727 |
|
|
2016
Q1 | $1.9M | Buy |
7,305
+635
| +10% | +$168K | 0.11% | 231 |
|
|
2015
Q4 | $2.04M | Buy |
6,670
+5,938
| +811% | +$1.71M | 0.12% | 220 |
|
|
2015
Q3 | $214K | Sell |
732
-2,600
| -78% | -$859K | 0.01% | 1435 |
|
|
2015
Q2 | $1.35M | Sell |
3,332
-14,612
| -81% | -$5.86M | 0.07% | 418 |
|
|
2015
Q1 | $7.58M | Buy |
17,944
+10,413
| +138% | +$4.1M | 0.37% | 27 |
|
|
2014
Q4 | $2.56M | Sell |
7,531
-1,947
| -21% | -$630K | 0.14% | 176 |
|
|
2014
Q3 | $3.13M | Sell |
9,478
-1,640
| -15% | -$541K | 0.19% | 121 |
|
|
2014
Q2 | $3.51M | Buy |
+11,118
| New | +$3.35M | 0.21% | 104 |
|
Other funds holding BIIB
Cubist Systematic Strategies's BIIB Position: Q3 2025 in Review
Cubist Systematic Strategies reduced its Biogen (BIIB) stake by 98% in Q3 2025, selling an estimated $7.38M and leaving 1,300 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.
Cubist Systematic Strategies first reported a position in BIIB in Q2 2014 and has held it in 44 quarters since. The position peaked at $29.4M in Q3 2022. 905 funds tracked by Wall St. Rank hold BIIB as of Q3 2025.
- Cubist Systematic Strategies held 1,300 shares of Biogen worth $182K as of Q3 2025.
- Cubist Systematic Strategies sold 54,619 Biogen shares in Q3 2025, an estimated $7.38M.
- Biogen made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2678 holding.
- Cubist Systematic Strategies first reported a position in Biogen in Q2 2014 and has held it in 44 quarters since.
- Cubist Systematic Strategies's Biogen position peaked at $29.4M in Q3 2022.
- 905 funds tracked by Wall St. Rank held Biogen as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.